ClinicalTrials.gg
CompletedNCT05241145Updated Feb 15, 2022

Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients

A Phase 1/2 interventional study of IVMED-80 and Placebo in Keratoconus and Corneal Ectasia, sponsored by iVeena Delivery Systems, Inc.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by iVeena Delivery Systems, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry.
  • Registered 2 years 11 months after the study started (first participant enrolled Feb 2019, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the cornea thereby halting the progressing corneal thinning and bulging seen in keratoconus. We conducted a Phase 1/2a study to evaluate the safety and preliminary efficacy of a 6-week and a 16-week regimen using IVMED-80 and studied its impact on ocular safety and the change/progression in patients' vision and clinical measurements.

Read the detailed description

Standard Operating Procedures:

This study was designed to evaluate the safety and preliminary efficacy of IVMED-80 (0.15 mg/mL copper sulfate pentahydrate) in controlling the progression of corneal changes which typically occur in keratoconus patients.

This was a randomized, double-masked, placebo-controlled, and single-site clinical trial with eligible patients randomly assigned to one of three treatment groups:

  • Group 1 (IVMED-6Wk) received topical copper sulfate eye drops 2x/day (BID) for 6 weeks and followed by an additional 20 weeks without treatment (total 26 weeks).
  • Group 2 (IVMED-16Wk) received topical copper sulfate eye drops BID for 16 weeks and followed for an additional 10 weeks without treatment (total 26 weeks).
  • Group 3 (Placebo) received IVMED-80 vehicle eye drops BID for 16 weeks and followed for an additional 10 weeks without treatment (total 26 weeks).

All patients were seen at Screening Visit, at Day 0 (Dispensing), and on Weeks 1, 3, 6, 12, 16, 21 and 26. In-office ophthalmology examinations used marketed medical diagnostic devices and routine clinical procedures. If a patient presents with two eyes meeting the eligibility criteria, the eye with the worst keratoconus based on maximum keratometry was selected as the Study Eye.

Any adverse events (AEs), suspected adverse events, and serious adverse events were recorded on the Adverse Event Report Form and in the patient's source documents. Laboratory, vital sign, or ECG abnormalities were recorded as AEs if medically relevant. The sponsor-investigator submitted a safety report to the review board no later than 15 calendar days after any suspected adverse reaction. Any unexpected fatal or life-threatening suspected adverse reactions was reported to the review board no later than 7 days after the sponsor-investigator's is made aware. Accidental or intentional overdose of the study drug or concomitant medication or discovery of pregnancy was reported to the Medical Monitor within 24 hours. Any AEs that led to a patient's withdrawal from the study were reported to the Medical Monitor within 30 days. In the case of an emergency, the Investigator could complete the subject treatment code breaking procedure. This was only done if awareness of the treatment had a direct impact on the subject's immediate medical management. The Medical Monitor was contacted prior to emergency unmasking or within 24 hours. The circumstances leading to unmasking of a subject were promptly communicated to the Sponsor and review board. A patient had the right to withdraw from the study at any time, for any reason, and without repercussion. The investigator had the right to withdraw a patient from the study in the event of an intercurrent illness, onset of pregnancy, adverse event (AE), treatment failure, or protocol violation. If a subject withdrew due to an AE(s), the reason for withdrawal was recorded as an adverse event. Subjects who failed to come to follow up visits and could not be contacted after 3 telephone calls followed by a certified letter were classified as "lost to follow-up".

Collected Data:

Corneal topography was obtained at every visit using the Oculus Pentecam. This device provided data for Maximum Central Keratometry (Kmax), Mean Central Keratometry (Kmean), Corneal Astigmatism, and Posterior Maximum Corneal Elevation.

The maximum central keratometry is a measure of the maximal corneal steepness and is a very commonly used in the diagnosis of keratoconus as well as monitoring and evaluating treatment effects. Normal Kmax is \<49.00 diopters.

The mean central keratometry is a measure of the mean corneal steepness and anterior curvature. It is one of the measures of corneal topography which is the evaluation of the anterior curvature of the cornea. Normal Kmean is \<47.20 diopters.

Corneal astigmatism is a measure of corneal irregularity leading to multiple focal points of light within the eye and impaired vision. Corneal astigmatism ranges greatly in magnitude and may be found in healthy patients to varying degrees, but it is also known to be present in keratoconus and worsens with disease progression. Keratoconus is the progressive and inferior bulging of the cornea. Therefore, corneal thickness is useful in diagnosis and disease or treatment monitoring. This was measured using the Oculus Pentecam at every visit. Central corneal thickness ranges from 472-651 micrometers and minimal thickness is normally >400 micrometers.

Intraocular pressure (IOP) above or below normal ranges may lead to pain or damage and may be affected by topical medications. IOP ranges from 8-21 millimeters of mercury.

An early sign of keratoconus is posterior thinning or "elevation". This measure is also useful in monitoring progression or treatment of the disease. Normal values are \<17 micrometers.

The Ocular Response Analyzer (ORA) or Oculus Corvis were used at each visit. These are noncontact tonometers that use a puff of air to investigate the dynamic reaction and surface deformation of the cornea. These instruments provide an in vivo assessment of corneal biomechanics (i.e., resistance to corneal deformation) which may be used to monitor the progression and treatment of corneal diseases such as keratoconus. Normal values for measured parameters vary in the literature with no consensus currently. Analyzed variables from these machines include the corneal resistance factor (CRF) and corneal hysteresis from the ORA and stiffness parameter highest concavity (SP-HC), stress-strain index (SSI), and peak distance from the Oculus Corvis.

Mean Best Corrected Distance Visual Acuity (BCVA) is the vision patients achieve with proper correction of refractive error, i.e., wearing glasses. Uncorrected distance visual acuity (UCVA) is without correction. A standard Snellen Visual acuity chart was used to measure visual acuity at every visit.

Endothelial cells are located on the posterior surface of the cornea and are responsible for dehydration of corneal stroma ensuring its clarity. Damage to these cells and decrease in cell density may be caused by cytotoxic of topical medications. Endothelial cell count (EEC) was assessed at the Screening, Day 0, Week 6, and Week 26 (exit) visits with a specular microscope. EEC ranges from >1,500 to 3,500 cells per square millimeter.

Patients with discomfort and redness upon instillation was evaluated at each study visit. the Investigator recorded patient responses concerning perceived discomfort and redness following instillation away from the clinic. The case report form stated, "Did the patient experience discomfort immediately after using the assigned study drops?". Possible answers were "No" or "Yes". A "Yes" response was graded on a 5 point scale ranging from 1(slight discomfort) to 5 (very uncomfortable). Similarly, redness was measured with a 0 to 5 scales: 0 (white conjunctiva) to 5 (completely red conjunctiva).

Routine ophthalmic examination variables (external slit-lamp examination and dilated fundus examination) were also obtained performed.

Data Quality Assurance:

The progress of the study was monitored by on-site visits and with the use of telephone calls, e mails, and written communication between personnel at the study sites and the sponsor's representatives. Site personnel weighed assigned treatment bottles at each visit to monitor compliance. The Investigator allowed the clinical monitors or designees to inspect all completed case report forms, subject records (e.g., source documents), signed informed consent forms, records of study medication receipt, storage, and dispensation, and regulatory files related to this study. Monitoring and study management followed Good Clinical Practices. Patient data required for the study were recorded on paper case report forms completed during each office visit. The site sent copies of all case report forms and other study records to the sponsor in the form of PDF files. PDF files, with images of case report forms and printouts from the measuring equipment, were reviewed by the sponsor, indexed and archived in a Dropbox folder with limited access. All data were entered into Microsoft Excel spreadsheets by a masked clinical research monitor. Key efficacy and safety data was reviewed by a second masked individual and differences reconciled prior to unmasking. Some questionable Pentecam images were reviewed and validated by the masked medical monitor and invalid data was not included in the database. All original documents and source documentation were stored at the study site. All study documentation and source documents were made available upon request for inspection by authorized representatives from the sponsor or regulatory authorities.

The Data Safety Monitoring Committee:

The Committee included Balamurali Ambati, M.D. and Arturo Chayet, M.D. Types of adverse events monitored for and reviewed included, but were not limited to, endophthalmitis, increased IOP, cystoid macular edema, and retinal detachment. Study progress and safety reports were created by the monitoring committee. Findings of the monitoring committee were submitted to the review board after each meeting. In addition, the monitoring committee reviewed the data if any participant experienced a serious, unexpected adverse event. The investigator will retain all essential study documents, including ICFs, source documents, CRFs, and drug accountability records for at least 5 years following the completion or discontinuation of the study, or longer if a longer period is required by relevant regulatory authorities. Records will be destroyed in a manner that ensures confidentiality.

Determination of Sample Size:

This was a first-in-human study designed to assess safety and preliminary efficacy. No formal hypothesis testing, formal power calculations or sample size calculations were used to determine sample size. A sample size of up to 36 patients was targeted based on establishing a reasonable number of patients to provide adequate safety and preliminary efficacy information to proceed to the next phase of clinical development.

Statistical and Analytical Plan:

The Statistical Analysis Plan (SAP) was developed prior to the database lock for the primary and secondary efficacy and safety variables. This plan identified the primary endpoints, analysis and populations, and also the handling of missing data. The SAP was signed and approved before the data were unmasked for analysis. This is a proof of concept study to determine viability of topical copper sulfate eyedrops at slowing progression of keratoconus. The number of subjects enrolled is appropriate for a proof of concept study and not necessarily powered to demonstrate statistically significant differences between the groups. Reported statistics were descriptive (e.g., means, variance) and comparing results baseline measures with t-tests. Missing data for keratometry measures, Kmax, were imputed using a last z-score carried forward analysis. For the keratometry measure of interest, Kmax, additional analysis with a longitudinal linear mixed effects model was performed. Difference in slopes or means at 26 weeks will be compared between the IVMED-16Wk and Placebo group. Baseline measurements will be considered the average of measurements collected at the screening and day 0 visits if both are available. Data points that appear to be outliers will be investigated and will not be excluded from the listings unless the clinical investigator concludes the value is not clinically possible. If a clinically impossible outlier was found, two analyses were performed, one with and without clinically impossible data with footnotes to indicate the analyses. Slit-lamp findings and non-ophthalmic adverse events though collected were not analyzed for the topline analysis.

02

Conditions studied

  • Keratoconus
  • Corneal Ectasia

Browse trials for

Keywords

  • Keratoconus
  • Corneal Ectasia
  • Copper
  • Micronutrients
  • Eye drops
  • Topical Therapy
03

In context

Keratoconus

313 studies on the registry are indexed under Keratoconus; 55 are open to participants now.

This study's enrollment of 38 is close to the median of 40 across 205 interventional studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

iVeena Delivery Systems, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Mild to moderate keratoconus and/or corneal ectasia post-LASIK or Photo-Refractive Keratectomy
  2. Age 18 to 40
  3. Minimum corneal thickness of > 350 microns
  4. Maximum corneal keratometry of 45 D to 67 D
  5. Absence of systemic comorbidities that pose a significant surgical risk
  6. Absence of ocular comorbidities
  7. Willing and able to comply with clinic visits and study-related procedures.
  8. Provide signed

Exclusion criteria

Exclusion Criteria:

  1. Significant central corneal scarring or hydrops
  2. Previous corneal surgeries
  3. Presence of pre-existing glaucoma, uveitis, uncontrolled diabetic retinopathy, or prior ocular trauma or prior intraocular surgery.
  4. Myopic degeneration with potential acuity less than 20/40 in the Study Eye.
  5. Down's Syndrome, retinitis pigmentosa, Ehlers-Danlos Syndrome, osteogenesis imperfecta (or other collagen disorder) or Anton's Syndrome.
  6. Prior retinal detachment involving the macula
  7. Received a sub-Tenon's injection of within the past 6 months, or any intravitreal injection within the past 6 months in the study eye prior to Visit 1
  8. Current use, or anticipated initiation during the study, of a systemic corticosteroid or an agent by any route (oral, injectables)
  9. History or current condition of substance or alcohol abuse within the past year
  10. Participation in a clinical trial with use of any drug or treatment within 30 days prior to Visit 1
  11. Employee of the study site or their immediate families.
  12. Pregnancy or planning to become pregnant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    IVMED-6Wk

    In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)

    Drug: IVMED-80

  • Experimental
    IVMED-16Wk

    In Group 2 (IVMED-16Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)

    Drug: IVMED-80

  • Placebo comparator
    Placebo

    In Group 3 (Placebo), patients instilled IVMED-80 vehicle solution eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)

    Other: Placebo

Interventions

  • DrugIVMED-80

    Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.

  • OtherPlacebo

    This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.

    Also known as: IVMED-80 Vehicle

06

What researchers measure

Primary outcomes

  1. Mean Maximum Central Keratometry (Kmax)

    Change in maximum central keratometry after the assigned treatment was compared with baseline measures. This will be evaluated with and without z-score imputation. It will also be evaluated with a linear mixed effects model.

    Time frame: 26 weeks

  2. Number of Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were defined as events requiring additional treatments or cessation of the study article for which the date of onset was on or after the date of first dose of double-masked study drug at Day 0.

    Time frame: 26 Weeks

  3. Mean Best Corrected Distance Visual Acuity (BCVA)

    Change in BCVA after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

Secondary outcomes

  1. Mean Corneal Astigmatism

    Corneal astigmatism after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

  2. Mean Central Keratometry (Kmean)

    The mean central keratometry after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

  3. Mean Posterior Maximum Corneal Elevation

    Mean Posterior Maximum Corneal Elevation after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

  4. Mean Endothelial Cell Count (ECC)

    Mean EEC after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

  5. Percentage of patients with discomfort and redness upon instillation

    Percentage of patients with discomfort and redness upon instillation over the study period was reported.

    Time frame: 26 Weeks

  6. Mean Corneal hysteresis

    Mean Corneal hysteresis after the assigned treatment was compared with baseline measures with the Ocular Response Analyzer.

    Time frame: 26 weeks

  7. Mean Corneal resistance factor (CRF)

    Mean Corneal resistance factor after the assigned treatment was compared with baseline measures with the Ocular Response Analyzer.

    Time frame: 26 weeks

  8. Mean Central Corneal Thickness (CCT)

    The mean CCT after the assigned treatment was compared with baseline measures.

    Time frame: 26 weeks

  9. Mean Minimal Corneal Thickness

    The mean Minimal Corneal Thickness after the assigned treatment was compared with baseline measures.

    Time frame: 26 weeks

  10. Mean Intraocular Pressure (IOP)

    The mean IOP after the assigned treatment was compared with baseline measures.

    Time frame: 26 weeks

  11. Mean Uncorrected Visual Acuity (UCVA)

    The mean UCVA after the assigned treatment was compared with baseline measures.

    Time frame: 26 Weeks

  12. Mean Stiffness parameter highest concavity (SP-HC)

    Mean SP-HC after the assigned treatment was compared with baseline measures with the Oculus Corvis.

    Time frame: 26 Weeks

  13. Mean Stress-strain index (SSI)

    Mean SSI after the assigned treatment was compared with baseline measures with the Oculus Corvis.

    Time frame: 26 Weeks

  14. Mean Peak distance

    Mean Peak distance after the assigned treatment was compared with baseline measures with the Oculus Corvis.

    Time frame: 26 Weeks

07

Study locations

1 site
  • Codet Vision Institute
    Tijuana, Baja California 22320, Mexico
08

References and documents

Publications

  • Olivares Jimenez JL, Guerrero Jurado JC, Bermudez Rodriguez FJ, Serrano Laborda D. Keratoconus: age of onset and natural history. Optom Vis Sci. 1997 Mar;74(3):147-51. doi: 10.1097/00006324-199703000-00025. PubMed 9159804 ↗
  • Wagner H, Barr JT, Zadnik K. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date. Cont Lens Anterior Eye. 2007 Sep;30(4):223-32. doi: 10.1016/j.clae.2007.03.001. Epub 2007 May 3. PubMed 17481941 ↗
  • Kymes SM, Walline JJ, Zadnik K, Sterling J, Gordon MO; Collaborative Longitudinal Evaluation of Keratoconus Study Group. Changes in the quality-of-life of people with keratoconus. Am J Ophthalmol. 2008 Apr;145(4):611-617. doi: 10.1016/j.ajo.2007.11.017. Epub 2008 Jan 28. PubMed 18226798 ↗

Individual participant data

Plan to share: Yes — IPD will be shared in a journal publication.

Time frame: Data will become available pending journal publication time frames.

Access criteria: Data will be displayed in figures and tables and as supplemental files in the published journal and accessibility will depend on journal open access policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jul 2020, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2022
First posted
Feb 15, 2022
StartActual
Feb 8, 2019
Primary completionActual
Jul 8, 2020
CompletionActual
Jul 8, 2020
Last update
Feb 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05241145
Lead sponsor
iVeena Delivery Systems, Inc.
Collaborators
Codet Vision Institute
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Feb 8, 2019
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020
Last update
Feb 15, 2022

Study contacts

Arturo Chayet, MD
principal investigator · Codet Vision Institute
Balamurali K. Ambati, MD, PhD
study director · iVeena Delivery Systems

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion